The road to conception for women with multiple sclerosis.

Multiple sclerosis conception disease modifying therapies family planning pregnancy

Journal

Multiple sclerosis journal - experimental, translational and clinical
ISSN: 2055-2173
Titre abrégé: Mult Scler J Exp Transl Clin
Pays: United States
ID NLM: 101668877

Informations de publication

Date de publication:
Historique:
received: 25 02 2021
accepted: 25 06 2021
entrez: 5 8 2021
pubmed: 6 8 2021
medline: 6 8 2021
Statut: epublish

Résumé

The objective of this prospective "real world" study is to gain insight into the different "roads to conception" that women with MS take as part of the prospective Canadian Multiple Sclerosis Pregnancy Study (CANPREG-MS). Participants are women with MS who are planning a pregnancy. Data cut-off for analyses was April 30, 2020. We believe this is the first prospective National study of women with MS planning pregnancies.The data are for the first 44 women enrolled of whom 26 achieved pregnancy by cut-off date. Seven women used assisted reproductive technologies (ARTs); 6 stopped disease modifying therapy (DMT) against their neurologists' recommendations; 6 had an interruption(s) in trying to conceive due to MS relapses, MRI-detected inflammation, or limited "windows of opportunity" between DMT courses. The study illustrates the roads that women take to conception, even if they are on the same therapy and have similar clinical expression of MS. Advice given by treating neurologists on washout periods show discrepancies. This paper highlights the real problem that there is no definitive, international consensus on managing these women due to the lack of "real world" data and thus the goal of CANPREG-MS is to provide such real world data.

Identifiants

pubmed: 34350028
doi: 10.1177/20552173211032313
pii: 10.1177_20552173211032313
pmc: PMC8287372
doi:

Types de publication

Journal Article

Langues

eng

Pagination

20552173211032313

Informations de copyright

© The Author(s) 2021.

Références

J Biomed Inform. 2009 Apr;42(2):377-81
pubmed: 18929686
Can J Neurol Sci. 2020 Jul;47(4):437-455
pubmed: 32654681
Mult Scler. 1999 Oct;5(5):349-54
pubmed: 10516779
Lancet Neurol. 2018 Feb;17(2):162-173
pubmed: 29275977
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Mult Scler. 2020 Oct;26(11):1410-1419
pubmed: 31368394
Mult Scler Relat Disord. 2015 Jan;4(1):6-17
pubmed: 25787048
Neurology. 2018 Oct 23;91(17):e1559-e1569
pubmed: 30266889
Neurol Ther. 2018 Dec;7(2):207-232
pubmed: 30167914
Int J MS Care. 2018 Jan-Feb;20(1):9-14
pubmed: 29507538
Mult Scler. 2020 Jun;26(7):829-836
pubmed: 30968734
Health Rep. 2012 Dec;23(4):7-13
pubmed: 23356040
Can J Neurol Sci. 2019 Oct 29;:1-6
pubmed: 31659949
Pract Neurol. 2019 Apr;19(2):106-114
pubmed: 30612100
BMC Neurol. 2013 Apr 25;13:37
pubmed: 23617555
Mult Scler. 2016 May;22(6):801-9
pubmed: 26920382
BMJ Open. 2020 Feb 17;10(2):e034355
pubmed: 32071184

Auteurs

Dessa Sadovnick (D)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

Maria Criscuoli (M)

Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada.

Irene Yee (I)

Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.

Robert Carruthers (R)

Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada.

Alice Schabas (A)

Faculty of Medicine, Division of Neurology, University of British Columbia, Vancouver, BC, Canada.

Penelope Smyth (P)

Department of Medicine (Neurology), University of Alberta, Edmonton, Alberta, Canada.

Classifications MeSH